Aggrey Ambali, Prof
Science, Technology and Innovation Policy
Fellow since 2013
Prof. Aggrey Ambali is currently serving as Head of Science, Technology and Innovation Hub (NSTIH) at the New Partnership for Africa's Development (NEPAD) Agency, where he oversees development and implementation of programs in education, health, and science and technology. He has also served in other positions at the NEPAD Agency, including Director of Policy Alignment and Program Development, Coordinator of the African Biosciences Initiative, and Coordinator of Science and Technology for the Southern Africa region.
He has been actively involved in science, technology and innovation programmes of the African Union. He coordinated the work of the African Union High Level Panel on Science, Technology and Innovation which was appointed in July 2012 and mandated to prepare a ten year African Union Science, Technology and Innovation strategy for Africa, 2014- 2024 (STISA 2024). Outside the NEPAD Agency, he served as an external member of Governing Council of the University of Namibia, and member of the Innovation Council of the Common Market for Eastern and Southern Africa (COMESA). He serves on several committees including the Technical Advisory Committee of the Biosafety Program of ICGEB, Chair of the Management Committee of the African Biosafety Network of Expertise (ABNE), member of the Advisory Panel of the Biosciences eastern and central Africa (BecA), etc.. Aggrey Ambali is currently coordinating the process of establishing a high level African Union panel on harnessing emerging technologies for Africa’s development. Aggrey Ambali obtained a PhD degree in Population Genetics from Dalhousie University, Canada, Masters of Science in Aquaculture from Asian Institute of Technology, Thailand and Bachelor of Science in Agriculture from University of Malawi. He served as a faculty member at the University of Malawi where he became a Professor of Biology in 2003.
Newton Isaac Kumwenda, Prof
Fellow of AAS since 2015
Born in 1958
Prof Kumwenda leads several successful studies; the PEPI-Malawi study was one of the first to establish that post-exposure chemoprophylaxis reduces risk of HIV acquisition. He also led the first HIV-1 phase I vaccine trial in Malawi in 2003 and the multicenter Phase III trial to evaluate the effectiveness of antiretroviral therapy to prevent the sexual transmission of HIV-1 in serodiscordant couples (HPTN052).
Prof Kumwenda established a state-of-the-art research laboratory and center in Blantyre with a team of 15 research staff only in 1996 to a multidisciplinary team of more than 200 in 2006. He also led the development of the research capacity centres to meet international standards for good clinical practice for clinical trials.
He has more than 80 scientific publications and has supervised more than 20 postgraduate students along with being involved in many capacity development programmes including being the first Director of as the wellcome Trust funded Southern Africa consortium for Research excellence (SACORE)
Prof Kumwenda is a member of the International Epidemiological Association (IEA) and has been a member of the IEA Councilor for Member: International AIDS Society (IAS).